8-K: enGene's Detalimogene Shows Stronger Efficacy in Bladder Cancer

enGene Holdings Inc. reports improved preliminary efficacy and favorable tolerability for its lead drug candidate, detalimogene, in high-risk bladder cancer patients following a protocol amendment.

Summary

• Preliminary data from the pivotal Cohort 1 of the LEGEND trial for detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC with CIS shows improved efficacy post-protocol amendment.
• For patients enrolled under the amended protocol (N=62), the anytime complete response (CR) rate was 63% (CI: 51-74), the 3-month CR rate was 56% (CI: 44-68), and the 6-month CR rate was 62% (CI: 46-76).
• Four patients who did not achieve CR at 3 months converted to CR at 6 months, and all five evaluable patients maintained CR at 9 months.
• The overall tolerability profile was favorable, with 42% of 125 patients experiencing at least one treatment-related adverse event (TRAE), mostly Grade 1/2. Only 2.4% experienced Grade 3 TRAEs, with no Grade 4/5 TRAEs or drug discontinuations due to Grade 3 TRAEs.
• The primary endpoint for Cohort 1 has been changed to CR rate at any time, consistent with other FDA-registered programs for BCG-unresponsive NMIBC.
• Enrollment for the pivotal Cohort 1 is complete with 125 patients, exceeding the target.
• Other cohorts (2a, 2b, 3) are actively enrolling, with 30, 45, and 36 patients enrolled respectively.
• The company had $202.4 million in cash, cash equivalents, and short-term investments as of October 31, 2025.

Sentiment

Score: 8

Explanation: The preliminary clinical data for detalimogene, particularly after the protocol amendment, shows a significant improvement in complete response rates and a favorable tolerability profile, positioning it competitively against other therapies. The completed enrollment of the pivotal cohort, FDA alignment on the primary endpoint, and a strong cash position into 2027 are all highly positive indicators for the company's development trajectory and potential market entry. The main caveat is the preliminary nature of the data and the need for long-term durability results.

Positives

• Improved 6-month complete response (CR) rate of 62% for patients treated under the amended protocol, up from 41% for pre-amendment patients.
• Four patients who initially did not achieve CR at 3 months successfully converted to CR at 6 months.
• All five evaluable patients who reached the 9-month assessment maintained a complete response.
• Favorable tolerability profile with mostly mild (Grade 1/2) treatment-related adverse events (TRAEs) in 42% of patients, and only 2.4% experiencing Grade 3 TRAEs, with no Grade 4/5 TRAEs.
• Very low rates of dose interruptions (1.6%) and discontinuations (0.8%) due to TRAEs.
• Pivotal Cohort 1 enrollment completed with 125 patients, exceeding the target.
• FDA has agreed to change the primary endpoint to "CR rate at any time," aligning with other approved therapies and potentially streamlining the approval pathway.
• Detalimogene is designed for ease of use, with fewer doses, short chair time, no special handling/storage requirements (2-8C), and no post-treatment patient precautions, making it attractive for high-volume urology practices.
• The DDX platform offers advantages like large genetic cargo capacity, non-immunogenicity, and low cost of goods.
• The company is well-capitalized with a projected cash runway into 2027.

Negatives

• Preliminary efficacy data for patients enrolled prior to the protocol amendment showed a markedly lower 12-month CR rate compared to FDA-approved products for BCG-unresponsive NMIBC.
• Long-term durability data is currently limited, especially for patients enrolled under the revised protocol, due to the heavily skewed enrollment curve delaying 12-month patient evaluations.
• The final patient count for efficacy evaluation is subject to FDA review and agreement on the Statistical Analysis Plan (SAP).
• The lead program is still an investigational drug therapy, and early Phase 1 testing is not sufficient to predict efficacy or safety.
• FDA's indication that Phase 2 may support BLA approval depends entirely on future Phase 2 results, which are not expected until 2026.

Risks

• No guarantee that detalimogene will successfully complete necessary clinical development phases, including achieving positive results in the pivotal cohort of the LEGEND study.
• No guarantee that clinical trial results or regulatory feedback will ultimately lead to a Biologics License Application (BLA) submission for, and the approval of, detalimogene.
• Preliminary clinical data may not predict the final results of the trial.
• Changes in the results from enGene's clinical trials could occur due to new data collected, subsequent analysis of existing data, and audit and verification procedures.
• The content and timing of decisions made by the U.S. Food and Drug Administration (FDA) and other regulatory authorities could impact development and approval.
• The company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites, enroll patients, and execute clinical development plans.
• The company's ability to secure regulatory approval on anticipated timelines.
• There may be additional risks that enGene presently knows or currently believes are immaterial that could also cause actual events and results to differ.

Future Outlook

The company anticipates providing a data update on the LEGEND trial's pivotal cohort in the second half of 2026, following FDA interactions and accumulation of sufficient 12-month CR data. A Biologics License Application (BLA) filing is expected in the second half of 2026, with potential FDA approval and commercial launch in 2027. The NMIBC market is forecasted to exceed $20 billion, and detalimogene is positioned to become a first-line therapy after BCG due to its efficacy, favorable safety, and ease of use. The company projects its cash runway into 2027.

Management Comments

• "We are pleased to report an improved 6-month CR rate for patients being treated with detalimogene under our amended protocol. With a competitive preliminary efficacy profile and potential for best-in-class tolerability and ease of use, we believe detalimogene could emerge as the first-line therapy for patients with high-risk, BCG-unresponsive NMIBC." Hussein Sweiti, M.D., MSc, Chief Medical Officer.
• "Careful selection of an appropriate bladder-sparing therapy is of utmost importance in creating a long-term strategy to maintain a patient's disease control and quality of life, while minimizing the logistical burden on patient and practice. I am pleased to see the positive trajectory of detalimogene's efficacy and tolerability data. Combined with its ease of use, detalimogene would be an attractive option to both patient and a busy urology practice." Suzanne Merrill, M.D., Senior Physician, Urologic Oncologist and Bladder Cancer Regional Lead, at Colorado Urology.
• "We are highly encouraged with the preliminary data from our LEGEND study, which support our planned BLA filing. Based on the emerging clinical profile and detalimogene's differentiated ease of use, we continue to believe there is a substantial commercial opportunity for detalimogene if approved." Ron Cooper, President and CEO.

Industry Context

The NMIBC market represents a significant unmet need, with bladder cancer being the 6th most common cancer and NMIBC accounting for 75-80% of diagnoses. Current treatments like BCG have chronic supply shortages, poor long-term tolerability, or poor efficacy, while radical cystectomy is a last resort with high morbidity. FDA guidance has been revised to support the development of new therapies, including single-arm studies, indicating a regulatory environment favorable to novel treatments. Detalimogene, as a non-viral gene therapy, aims to address these gaps by offering a novel class of drug with a favorable safety profile and ease of use, designed for seamless integration into high-volume urology practices, which are often strained by staff shortages and revenue pressures. The market is forecasted to be over $20 billion, highlighting the substantial commercial opportunity for effective new therapies.

Comparison to Industry Standards

• Efficacy (6-month CR rate): Detalimogene Post-Amendment (62%) compares favorably to Cretostimogene (BOND-002: 44%), Keytruda (KEYNOTE-057: 34%), and Adstiladrin (NCT02773849: 41%). It is comparable to Cretostimogene (BOND-003: 63%), Inlexzo (SunRISe-1: 59%), and Anktiva + BCG (QUILT 3.032: 56%).
• Anytime CR Rate: Detalimogene Post-Amendment (63%) is within the range of other novel products, though some comparators like Inlexzo (SunRISe-1: 82%) and Cretostimogene (BOND-003: 76%) show higher rates.
• Tolerability (Any Grade TRAEs/ADRs): Detalimogene (42% for n=125) trends towards best-in-class among investigational agents compared to Cretostimogene (63% for n=112). When compared to approved products, it is lower than Inlexzo (84%) and Adstiladrin (66%), but higher than Anktiva + BCG (24%) and Keytruda (11%).
• Ease of Use: Detalimogene, as a non-viral gene therapy, offers logistical simplicity with no complex shipping/storage, short single-step administration, no viral/bacterium decontamination, no post-treatment patient precautions, and no requirement for specially qualified staff/facility, differentiating it from viral gene therapies, chemo device combinations, bacterial therapies, and checkpoint inhibitors.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, potential for BLA submission and approval, and a strong cash position, which could lead to increased share value.
• Patients (NMIBC): Potential for a new, effective, and well-tolerated treatment option that could become a first-line therapy after BCG, offering bladder preservation and improved quality of life.
• Urologists/Healthcare Providers: Detalimogene's ease of use, streamlined administration, and favorable safety profile could reduce logistical burdens and integrate seamlessly into high-volume practices.
• Employees: Continued progress in clinical development and potential commercialization could lead to job security and growth opportunities.
• Regulatory Authorities: The company's engagement with the FDA and alignment on endpoints demonstrate adherence to regulatory pathways.

Next Steps

• Engage with the FDA on a statistical analysis plan (SAP) to determine the final efficacy evaluable population.
• Accumulate sufficient 12-month complete response (CR) data points.
• Provide a data update on the LEGEND trial's pivotal cohort in the second half of 2026.
• File the Biologics License Application (BLA) in the second half of 2026.
• Potential FDA approval and commercial launch in 2027.
• Continue enrollment and evaluation in Cohorts 2a, 2b, and 3 of the LEGEND trial.

Key Dates

Recommendation

The preliminary data from the LEGEND trial's pivotal cohort, especially post-protocol amendment, demonstrates a significant improvement in complete response rates (62% at 6 months) and a highly favorable tolerability profile, positioning detalimogene as a potentially best-in-class therapy for BCG-unresponsive NMIBC. The FDA's agreement to change the primary endpoint to "CR rate at any time" de-risks the regulatory pathway, aligning it with other approved products. With pivotal cohort enrollment complete, a clear path to BLA submission in 2H 2026, and a potential launch in 2027, the company is on track for a major value inflection point. The substantial market opportunity (>$20B NMIBC market) and the company's strong cash position ($202.4M into 2027) further bolster the investment case. While long-term durability data is still pending, the early efficacy and safety signals are compelling, suggesting a strong likelihood of future success and significant upside potential.

Keywords

detalimogene voraplasmid, NMIBC, bladder cancer, BCG-unresponsive, gene therapy, clinical trial, LEGEND study, Phase 2, complete response rate, DDX platform, oncology, biotechnology, FDA, RMAT, Fast Track